Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

CNN’s Ben Wedeman dives deep underground in Rome to explore the Aqua Virgo, an ancient aqueduct that continues to supply water to the Trevi Fountain and other landmarks. At least 20,000 federal ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...

Amgen (AMGN) came out with quarterly earnings of $5.31 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $4.71 per share a year ago. These figures are ...

Amgen has inaugurated its new drug substance facility in the US after announcing a $1bn further expansion at the North ...

The Thousand Oaks, California-based company said it had net income of $1.16 per share. Earnings, adjusted for non-recurring costs, came to $5.31 per share. The results surpassed Wall Street ...

“Medicines manufactured here in Holly Springs will help families worldwide. Think about that for a second.” In 2021, Amgen received state and local incentives to establish its drug substance ...